Truist on Viridian Therapeutic (VRDN): 'Ele' Positioned to Hit Proptosis Bar'
Tweet Send to a Friend
Truist Securities analyst Greg Renza reiterated a Buy rating and $40.00 price target on Viridian Therapeutic (NASDAQ: VRDN).The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
